Lanthanum Chloride Sensitizes Cisplatin Resistance of Ovarian Cancer Cells via PI3K/Akt Pathway

Shanyu Fang; Ping Zhang; Xinping Chen; Fujun Liu; Fen Wang

doi:10.3389/fmed.2021.776876

Lanthanum Chloride Sensitizes Cisplatin Resistance of Ovarian Cancer Cells via PI3K/Akt Pathway

Front Med (Lausanne). 2021 Dec 15:8:776876. doi: 10.3389/fmed.2021.776876. eCollection 2021.

Authors

Shanyu Fang¹, Ping Zhang², Xinping Chen¹, Fujun Liu¹, Fen Wang¹

Affiliations

¹ Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
² Department of Otorhinolaryngology Head and Neck Surgery, Jiujiang University Clinical Medical College, Jiujiang University Hospital, Jiujiang, China.

Abstract

Our previous study manifested that lanthanum chloride (LaCl₃) can enhance the anticancer ability of cisplatin (DDP) in ovarian cancer cells. Here, ovarian cancer cells SKOV3 and SKOV3/DDP were subjected to DDP and LaCl₃. Cell viability, apoptosis, DNA repair, and PI3K/Akt pathway were detected. LaCl₃ induced more cell death and apoptosis caused by DDP in two cell lines, accompanied by upregulation of Bax and Cleaved caspase 3 proteins, and downregulation of Bcl-2 protein. LaCl₃ also could decrease RAD51 protein by inactivation of the PI3K/Akt pathway. These data indicated that LaCl₃ could be a potential drug to modulate DDP resistance by inactivating of PI3K/Akt pathway and attenuating DNA repair in ovarian cancer.

Keywords: Akt; PI3K; cisplatin resistance; lanthanum chloride; ovarian cancer.